Technical Analysis for SRPT - Sarepta Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 117.87 -3.12% -3.80
SRPT closed down 3.37 percent on Monday, May 20, 2019, on 84 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
8 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical SRPT trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.26%
Fell Below 50 DMA Bearish 0.26%
Bollinger Band Squeeze Range Contraction 0.26%
NR7 Range Contraction 0.26%
NR7-2 Range Contraction 0.26%
Multiple of Ten Bearish Other 0.26%
BB Squeeze Started Range Contraction 0.26%
50 DMA Support Bullish -3.12%
NR7 Range Contraction -3.12%
BB Squeeze Ended Range Expansion -3.12%

Older signals for SRPT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Duchenne Muscular Dystrophy Therapeutic Gene Modulation Antisense RNA
Is SRPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 14 This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note
May 14 Catabasis Pharma reports Q1 results; shares up 5% premarket on Solid Bio selloff
May 12 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript
May 10 Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript
May 9 Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT
May 9 Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
May 9 When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?
May 9 Sarepta a "Fresh Pick" at Baird in premarket analyst action
May 9 Wall Street Breakfast: Global Markets Suffer As U.S.-China Dispute Intensifies
May 8 Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
See more SRPT news...
Indicators
Indicator Value
52 Week High 176.5
52 Week Low 86.55
Average Volume 1,104,155
200-Day Moving Average 128.0722
50-Day Moving Average 121.3144
20-Day Moving Average 118.611
10-Day Moving Average 118.075
Average True Range 5.549
ADX 11.87
+DI 20.3041
-DI 22.6576
Chandelier Exit (Long, 3 ATRs ) 108.483
Chandelier Exit (Short, 3 ATRs ) 128.052
Upper Bollinger Band 124.3812
Lower Bollinger Band 112.8408
Percent B (%b) 0.41
BandWidth 9.72962
MACD Line -0.6745
MACD Signal Line -1.1814
MACD Histogram 0.5069
Fundamentals Value
Market Cap 7.55 Billion
Num Shares 64.2 Million
EPS -2.34
Price-to-Earnings (P/E) Ratio -50.24
Price-to-Sales 53.98
Price-to-Book 6.98
PEG Ratio 231.25
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 123.98
Resistance 3 (R3) 124.20 122.29 122.91
Resistance 2 (R2) 122.29 120.66 122.18 122.55
Resistance 1 (R1) 119.93 119.65 118.98 119.71 122.20
Pivot Point 118.02 118.02 117.54 117.91 118.02
Support 1 (S1) 115.66 116.39 114.71 115.44 112.94
Support 2 (S2) 113.75 115.38 113.64 112.59
Support 3 (S3) 111.39 113.75 112.23
Support 4 (S4) 111.17